Pharmaceutical company Breckenridge Pharmaceutical Inc reported on Tuesday the receipt of US Food and Drug Administration final approval for an Abbreviated New Drug Application for Erlotinib Hydrochloride Tablets (generic Tarceva) in EQ 25mg base, EQ 100mg base and EQ 150mg base strengths for the treatment of non-small cell lung cancer and pancreatic cancer.
The Abbreviated New Drug Application of Erlotinib Hydrochloride Tablets is reportedly held by Natco Pharma Limited and developed in collaboration with MEDIK Ltd.
Under Breckenridge's marketing, sale and distribution agreement, the Erlotinib Hydrochloride Tablets will be manufactured and supplied by Natco and Breckenridge plans to launch the product immediately.
According to industry sales data, Tarceva and its therapeutic equivalents generated annual sales of approximately USD145m in the year ended 30 September 2019.
US FDA approves two applications for first Eliquis (apixaban) generics
Amneal Names George, Kiely and Yanai to Board of Directors
Civica Rx, Hikma to Ship Heparin and Seven Other Essential Injectable Medicines
US FDA grants approval to Meitheal Pharmaceuticals' Enoxaparin Sodium Injection
BioDuro names Dr Kent Payne as president of Global CMC Solutions
US FDA Approves Amneal ANDA for Generic Carafate
Dr Reddy's Laboratories reports availability of Deferasirox Tablets for oral suspension in US market
Amneal Launches Generic Revatio for Oral Suspension and Generic Amicar Tablets
Dr Reddy's Laboratories unveils Bortezomib for Injection 3.5 mg/vial in the US